JPMorgan Chase & Co. raised its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 1,021.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,165 shares of the company's stock after acquiring an additional 61,174 shares during the quarter. JPMorgan Chase & Co. owned about 0.23% of Aerovate Therapeutics worth $178,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in Aerovate Therapeutics by 310.8% in the third quarter. Barclays PLC now owns 18,972 shares of the company's stock valued at $39,000 after acquiring an additional 14,354 shares during the last quarter. Ieq Capital LLC bought a new position in shares of Aerovate Therapeutics in the 4th quarter valued at about $38,000. Corient Private Wealth LLC acquired a new stake in shares of Aerovate Therapeutics during the 4th quarter worth approximately $98,000. FNY Investment Advisers LLC bought a new stake in shares of Aerovate Therapeutics during the fourth quarter worth approximately $198,000. Finally, Deltec Asset Management LLC acquired a new position in Aerovate Therapeutics in the fourth quarter valued at approximately $514,000.
Aerovate Therapeutics Stock Performance
AVTE traded down $1.41 during trading on Wednesday, reaching $10.09. 424,316 shares of the company's stock were exchanged, compared to its average volume of 17,925. The company's fifty day moving average price is $79.90 and its 200-day moving average price is $85.85. The firm has a market capitalization of $292.46 million, a PE ratio of -3.37 and a beta of 0.95. Aerovate Therapeutics, Inc. has a fifty-two week low of $43.75 and a fifty-two week high of $884.98.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported ($3.15) EPS for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. Research analysts forecast that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.
Aerovate Therapeutics Announces Dividend
The firm also recently announced a dividend, which was paid on Monday, April 28th. Shareholders of record on Friday, April 25th were issued a dividend of $84.00 per share. The ex-dividend date was Tuesday, April 29th.
About Aerovate Therapeutics
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Further Reading
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
